Erdafitinib Erdafitinib (also known as JNJ-42756493) is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, Erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumour cell proliferation and tumour cell death in FGFR-overexpressing tumour cells. FGFR, upregulated in many tumour cell types, is a receptor tyrosine kinase essential to tumour cell proliferation, differentiation and survival. Astex Pharmaceuticals discovered this drug and licensed it to Janssen Pharmaceuticals for further development. Erdafitinib has been used in trials studying the basic science and treatment of Tumour or Lymphoma . Common Name: Erdafitinib Synonyms : JNJ-42756493; JNJ42756493; JNJ 42756493; G-024; JNJ-493 IUPAC Name : N...